Arbutus Biopharma (STU:I9DN) LT-Debt-to-Total-Asset : 0.01 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Arbutus Biopharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Arbutus Biopharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.01.

Arbutus Biopharma's long-term debt to total assets ratio declined from Mar. 2023 (0.01) to Mar. 2024 (0.01). It may suggest that Arbutus Biopharma is progressively becoming less dependent on debt to grow their business.

Arbutus Biopharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for Arbutus Biopharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma LT-Debt-to-Total-Asset Chart

Arbutus Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.02

0.01

Arbutus Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

Arbutus Biopharma LT-Debt-to-Total-Asset Calculation

Arbutus Biopharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1.232	/	132.416
	=	0.01

Arbutus Biopharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	1.087	/	138.267
	=	0.01

Arbutus Biopharma (STU:I9DN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Arbutus Biopharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Arbutus Biopharma (STU:I9DN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (STU:I9DN) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ABUS:USA

Address

701 Veterans Circle, Warminster, PA, USA, 18974

Website

http://www.arbutusbio.com

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Arbutus Biopharma (STU:I9DN) Headlines

No Headlines